We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Crimean-Congo Haemorrhagic Fever Vaccine Tested in Humans for First Time

A person having their temperature checked.
Credit: Mufid Majnun / Unsplash.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 2 minutes

A University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to volunteers for the first time.


The clinical trial of the ChAdOx2 CCHF vaccine aims to confirm its safety and understand how individuals develop immunity following vaccination. 


The study is led by Professor Teresa Lambe, Principal Investigator at the Oxford Vaccine Group (OVG) and Pandemic Sciences Institute (PSI) at the University of Oxford. Professor Lambe co-designed the Oxford/AstraZeneca COVID-19 vaccine and her team have been developing a vaccine against CCHF using similar technology for the last 5 years.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

The vaccine is being administered to healthy volunteers ages 18 – 55 in the Oxfordshire area, with participants receiving two doses of the vaccine 12 weeks apart. Participants are being closely monitored for the next 12 months to understand how they respond to the vaccine and whether they make antibodies against the CCHF virus. If they do, this would be the first step in creating a new vaccine against CCHF and a milestone for pandemic preparedness.


Professor Teresa Lambe, Calleva Head of Vaccine Immunology in the Department of Paediatrics and a Professor of Vaccinology and Immunology at the Oxford Vaccine Group and Pandemic Sciences Institute, University of Oxford said: “There are currently no approved vaccines or treatments for CCHF, and yet sadly up to 40 per cent of people admitted to hospital with the disease will die. In the absence of a vaccine, the only way to reduce infection is to raise awareness of the risk factors and signs of the disease.


“This trial is an important step in our development of a vaccine, which we hope will offer a real-life solution to keep people safe from this deadly virus.”


CCHF is a life-threatening disease caused by a virus that is mainly spread by ticks. CCHF outbreaks are an ongoing threat to public health. The disease is fatal in up to 40 per cent of hospital-admitted cases, and it is difficult to prevent and treat as there are currently no approved treatments or vaccines.  Endemic in all of Africa, the Balkans, the Middle East and Asia, CCHF is now spreading to other areas including parts of Europe. The World Health Organization estimates that about 3 billion people live in areas at risk of the disease. There is an urgent and ongoing need to develop vaccines against CCHF as it has the potential to lead to a future pandemic.


The ChAdOx2 CCHF vaccine is based on the ChAdOx2 vector – a weakened version of a common cold virus (adenovirus) that has been genetically modified so that it is impossible for it to replicate in humans. It is similar to the technology used successfully in the Oxford-AstraZeneca COVID-19 vaccine.


Katrina Pollock, Clinician Scientist in the Vaccinology Department of Paediatrics, University of Oxford said: “Here at the Oxford Vaccine Group, we are responding to this public health threat by developing a vaccine to protect against CCHF”.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.